RecruitingNot ApplicableNCT06911931

Visual Perception in Schizophrenia

Visual Perception in Schizophrenia: Assessing Predictive Processing in the Earliest Stages of the Visual Cortical Hierarchy


Sponsor

University of Rochester

Enrollment

84 participants

Start Date

Nov 3, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to identify novel markers of psychosis using electroencephalography (EEG).


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria8

  • All Subjects
  • Aged 18-65
  • /32 visual acuity or better (using in-house optical correction, if necessary)
  • An ability to speak English well enough to complete study assessments and to consent to the study
  • Subjects with Schizophrenia-Spectrum Disorder
  • Meets DSM-5 diagnostic criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder as confirmed by the Structured Interview for DSM-5 (SCID-5).
  • Subjects with Bipolar Disorder
  • Meets DSM-5 diagnostic criteria for bipolar disorder (type I, II, or unspecified) as confirmed by the Structured Interview for DSM-5 (SCID-5).

Exclusion Criteria25

  • All subjects
  • Presence of characteristics that could impair one's ability to comprehend the nature of the study, provide informed consent, or understand the assessment questions, including the following:
  • Subject cannot read and understand the instructions well enough to complete the tasks or cannot provide informed consent.
  • Intellectual impairment (WRAT-5 score \< 70) (at the discretion of experimenter);
  • Actively intoxicated, as shown via patient self-report or staff report;
  • Substance use disorder in the past 3 months;
  • Subject considered high risk for suicidal acts (i.e., active suicidal ideation as determined by clinical interview OR any suicide attempt in 30 days prior to screening);
  • Subject violence (involving severe/lethal means or violence occurring in prior 6 months) or extreme agitation.
  • Being in a current manic state
  • Head injury with loss of consciousness greater than 10 minutes (at the discretion of the experimenter).
  • Subject has had electroconvulsive therapy (ECT) in the past 8 weeks;
  • Diagnosed with a neurological condition (tumor, stroke, brain injury) or neurological disorder, including seizure disorders. Diagnosed with pervasive developmental disorder (phone screen or medical records)
  • Lazy eye or squint or other known ocular pathology
  • Healthy Control Subjects
  • Any lifetime psychotic disorder or history of psychiatric hospitalization (self disclosure);
  • Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days (self-disclosure); iii. First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder.
  • Case-match Control Non-ill Subjects
  • Any lifetime psychotic disorder (as assessed by SCID/or SSD);
  • Recurrent depressive episodes or being in a current depressive episode (as assessed by SCID/or SSD)
  • Persistent threshold psychotic symptoms
  • History of psychiatric hospitalization;
  • Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days
  • First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder.
  • Bipolar Subjects
  • Persistent threshold psychotic symptoms

Interventions

OTHEREEG measure of visual processing

Non-invasive scalp EEG measure of early cortical visual processing.


Locations(1)

University of Rochester

Rochester, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06911931


Related Trials